ZIBOR 2.500 IU Solution for injection (2021)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
1. Name of the medicinal product
Zibor 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringes.
2. Qualitative and quantitative composition
Bemiparin sodium: 2500 IU (anti Factor Xa*) per 0.2 ml pre-filled syringe (equivalent to 12500 IU (antiFactor Xa*) per millilitre solution for injection). Potency is described in International anti-Factor ...
3. Pharmaceutical form
Solution for injection in pre-filled syringes. Colourless or slightly yellowish, clear solution, free of visible particles.
4.1. Therapeutic indications
Prevention of thromboembolic disease in patients undergoing general surgery. Prevention of clotting in the extracorporeal circuit during haemodialysis.
4.2. Posology and method of administration
WARNING: The different low molecular weight heparins are not necessarily equivalent. Therefore compliance with the dosage regimen and the specific method of use for each of these medicinal products is ...
4.3. Contraindications
Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1. Hypersensitivity to heparin or substances of porcine origin. History of confirmed or suspected immunologically ...
4.4. Special warnings and precautions for use
Do not administer by the intramuscular route. Due to the risk of haematoma during bemiparin administration, the intramuscular injection of other agents should be avoided. When using daily doses of bemiparin ...
4.5. Interaction with other medicinal products and other forms of interaction
Bemiparin interactions with other medicinal products have not been investigated and the information given on this section is derived from data available from other LMWHs. The concomitant administration ...
4.6. Pregnancy and lactation
Pregnancy Animal studies have not shown any evidence of teratogenic effects with the use of bemiparin (see section 5.3). For bemiparin, clinical data on exposed pregnancies are limited. However, caution ...
4.7. Effects on ability to drive and use machines
Zibor has no or negligible influence on the ability to drive and use machines.
4.8. Undesirable effects
The most commonly reported adverse reaction is haematoma and/or ecchymosis at the injection site, occurring in approximately 15% of patients receiving Zibor. Osteoporosis has been associated with long-term ...
4.9. Overdose
Bleeding is the main symptom of overdosage. If bleeding occurs bemiparin should be discontinued depending on the severity of the haemorrhage and the risk of thrombosis. Minor haemorrhages rarely need specific ...
5.1. Pharmacodynamic properties
Pharmacotherapeutic group: antithrombotic agent, heparin group ATC code: B01AB12 Bemiparin sodium is a LMWH obtained by depolymerization of heparin sodium from porcine intestinal mucosa. Its mean molecular ...
5.2. Pharmacokinetic properties
The pharmacokinetic properties of bemiparin have been determined by measuring the plasma anti-Xa activity using the amydolitic method; it is based on reference to the W.H.O. First International Low Molecular ...
5.3. Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction. Acute and repeated dose toxicity ...
6.1. List of excipients
Water for injections
6.2. Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
6.3. Shelf life
2 years. After first opening, Zibor should be used immediately.
6.4. Special precautions for storage
Do not store above 30°C. Do not freeze.
6.5. Nature and contents of container
0.2 ml solution in pre-filled syringe (Type I glass) with a plunger rod (polypropylene), rubber plunger stopper (chlorobutyl) and injection needle (stainless steel). Packs of 2, 6, 10, 30 and 100 syringes. ...
6.6. Special precautions for disposal and other handling
Single-dose container. Discard any unused content. Do not use if the protective package is opened or damaged. Only clear colourless or slightly yellowish solutions, free of visible particles, should be ...
7. Marketing authorization holder
Frosst Ibérica, S.A. Via Complutense 140, Alcalá de Henares, 28805 Madrid, Spain
8. Marketing authorization number(s)
PA1769/001/001
9. Date of first authorization / renewal of the authorization
Date of first authorisation: 03 May 2002 Date of last renewal: 09 March 2010
10. Date of revision of the text
April 2021
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: